Abstract Number: 1016 • 2017 ACR/ARHP Annual Meeting
The Genetic Biomarkers to Predicting Response of TNF Inhibitors Treatment in Rheumatoid Arthritis
Background/Purpose: Although pharmacogenetic studies of TNF inhibitors (TNFi) response presented the estimates of high heritability, only few loci with suggestive weak association as biomarkers for…Abstract Number: 1017 • 2017 ACR/ARHP Annual Meeting
Investigation of Differential Methylation As a Potential Biomarker of Methotrexate Response in Patients with Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) is the first-line disease modifying anti-rheumatic drug for the treatment of rheumatoid arthritis (RA). However, many patients do not respond adequately or…Abstract Number: 1018 • 2017 ACR/ARHP Annual Meeting
Comprehensive Identification of Differentially Methylated Regions Associated with Systemic Sclerosis in Dermal Fibroblasts from African-American Patients
Background/Purpose: The etiology and reasons underlying the ethnic disparities in systemic sclerosis (SSc) remain unknown. African-Americans are disproportionally affected by SSc, yet dramatically underrepresented in…Abstract Number: 1019 • 2017 ACR/ARHP Annual Meeting
Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment
Background/Purpose: Despite the success of anti-TNF therapies in RA, ~ 30 % of patients are non-responders. Several studies have focused on understanding the biology underlying…Abstract Number: 1020 • 2017 ACR/ARHP Annual Meeting
The Inflammatory and Proliferative Synovial Lesion in Post-Infectious Lyme Arthritis Results from Impaired Wound Healing
Background/Purpose: Lyme arthritis (LA) is initially triggered by Borrelia burgdorferi infection, but in some patients, the synovitis persists despite 2-3 months of antibiotic therapy and…Abstract Number: 1021 • 2017 ACR/ARHP Annual Meeting
GWAS of Gout in Patients with Hyperuricemia Identified Many Possible New Candidate Risk Alleles
Background/Purpose: Virtually all gout patients have high levels of uric acid in the blood (hyperurincemia, HU), but approximately 80% of patients with HU will never…Abstract Number: 1022 • 2017 ACR/ARHP Annual Meeting
A Personalized Medicine Approach to Improve the Prediction of Azathioprine-Induced Pancreatic Injury: Preliminary Results
Background/Purpose: Azathioprine (AZA) is used to treat rheumatic diseases and to prevent transplant rejection. There is marked variability in toxicity to azathioprine; one such toxicity…Abstract Number: 1023 • 2017 ACR/ARHP Annual Meeting
The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)
Background/Purpose: Current serological tests are not sufficiently accurate in differentiating between HC and those with autoimmune rheumatic diseases. We developed the iCHIP antigen microarray to…Abstract Number: 1024 • 2017 ACR/ARHP Annual Meeting
High-Throughput Proteomic Profiling Identifies Dysregulated Proteins in Neonatal-Onset Multisystem Inflammatory Disease (NOMID) That Respond to IL-1blocking Treatment
Background/Purpose: Neonatal-onset multisystem inflammatory disease (NOMID) is an IL- 1 mediated autoinflammatory disease caused by a gain-of-function mutations in NLRP3that results in constitutive activation of…Abstract Number: 1025 • 2017 ACR/ARHP Annual Meeting
Submetabolome Profiling with Differential Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry and a Universal Metabolome Standard Reveals a Metabolite Profile with 99% Accuracy for Rheumatoid Arthritis
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is hampered by suboptimal accuracy of currently available serological biomarkers. Recent advancements in metabolomic profiling include dansylation liquid…Abstract Number: 1026 • 2017 ACR/ARHP Annual Meeting
Gene Expression Analysis Reveals Common Pathways of Tissue Pathogenesis in Lupus Organ Involvement
Background/Purpose: Lupus is a prototypic autoimmune disease characterized by B cell hyperactivity, autoantibody formation and resultant tissue damage. The mechanisms underlying tissue pathology in lupus…Abstract Number: 1027 • 2017 ACR/ARHP Annual Meeting
Quantification of Leukocytes’ Secretome to Guide Diagnosis and Treatment Options in Patients with Suspected Chronic Auto-Inflammatory Syndromes
Background/Purpose: Auto-inflammatory syndromes are inherited conditions characterized by recurrent inflammation (fever, abdominal pain, dermatitis, arthritis). Diagnosis and treatments are challenging as detection rate of mutations…Abstract Number: 1028 • 2017 ACR/ARHP Annual Meeting
Association of a Non-Synonymous, Loss-of-Function, Variant in NOD2 with Reduced Tissue Damage in ACPA +Ve RA
Background/Purpose: The functional capacity of individuals with rheumatoid arthritis (RA) is related to the severity of damage to bone and cartilage within joints. This is…Abstract Number: 1029 • 2017 ACR/ARHP Annual Meeting
What to Measure after Arthroplasty? Confirmation of a Core Domain Set
Background/Purpose: The Outcomes Measures in Rheumatology Trials (OMERACT) TJR Working Group has proposed six core domains that would constitute a standardized measurement set that can…Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting
Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis
Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
ACR Meeting Abstracts